Exhibit 1.3
Execution Version
AMENDMENT NO. 1 TO
OPEN MARKET SALE AGREEMENT
March 2, 2020
This Amendment No. 1 (“Amendment No. 1”) amends that certain Open Market Sale AgreementSM, dated as of May 10, 2019 (the “Agreement”), by and between Wave Life Sciences Ltd. (the “Company”) and Jefferies LLC, as sales agent and/or principal (the “Agent”). Defined terms used herein and not otherwise defined shall have the meaning assigned to such terms in the Agreement.
WITNESSETH THAT:
WHEREAS, Section 8(i) of the Agreement permits the Company and the Agent to amend the Agreement;
WHEREAS, the Company will not be “well-known seasoned issuer” as such term is defined in Rule 405 under the Securities Act of 1933, as amended, upon the filing of the Annual Report on Form 10-K for the year ended December 31, 2019; and
WHEREAS, the Company and the Agent now desire to amend the Agreement as provided herein.
NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Agent agree as follows:
1. The definition of Registration Statement contained in Section 2(a) of the Agreement shall be deemed to include any post-effective amendment to the Registration Statement.
2. Section 2(yy) of the Agreement is amended and restated in its entirety as set forth below:
“Well Known Seasoned Issuer. (i) At the original effectiveness of the Registration Statement and (ii) at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the Securities Act) made any offer relating to the Shares in reliance on the exemption of Rule 163 under the Securities Act, the Company was a “well known seasoned issuer” (as defined in Rule 405).”
3. EXHIBIT B of the Agreement is amended such that the Notice Parties for the Company shall be amended and restated as set forth below:
Paul Bolno, M.D. (pbolno@wavelifesci.com)
Linda Rockett (lrockett@wavelifesci.com)
4. The Company agrees to pay the reasonable and documented fees and disbursements of the Agent’s counsel in connection with this Amendment No 1., provided that the amount payable by the Company with respect to such fees and disbursements of the Agent’s counsel shall not exceed $5,000.
5. Section 8(i) of the Agreement is supplemented and amended such that this Amendment No. 1 and the Agreement, as amended hereby, constitute the entire agreement of the parties to the Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof and thereof.
6. This Amendment No. 1 shall be deemed effective on the date first set forth above.